TrialBMC cancer2018
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
Marco Racioppi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
39 papers cite it
this paperpooled ittrialcites it